Valneva SE (WBO:VLA) EBIT: €-96.6 Mil (TTM As of Mar. 2026)


WBO:VLA Valneva SE WBO:VLA
56 GF Score
Price €2.23
GF Value €2.46
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE EBIT?

Valneva SE WBO:VLA +1.32% 56 EBIT is €-96.6 Mil as of Mar. 2026. GuruFocus rates WBO:VLA with a GF Score™ of 56/100 and a GF Value™ of €2.46 (Fairly Valued). The stock has 6 warning signs investors should review.

Valneva SE's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-26.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-96.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Valneva SE's annualized ROC % for the quarter that ended in Mar. 2026 was -39.47%. Valneva SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -62.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Valneva SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.31%.

Valneva SE  (WBO:VLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Valneva SE's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-94.784 * ( 1 - 0% )/( (257.732 + 222.582)/ 2 )
=-94.784/240.157
=-39.47 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=398.836 - 31.454 - ( 109.65 - max(0, 93.334 - 222.541+109.65))
=257.732

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=372.013 - 44.166 - ( 105.265 - max(0, 94.218 - 201.439+105.265))
=222.582

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Valneva SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-104.628/( ( (138.031 + max(40.121, 0)) + (133.608 + max(22.967, 0)) )/ 2 )
=-104.628/( ( 178.152 + 156.575 )/ 2 )
=-104.628/167.3635
=-62.52 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(27.733 + 50.232 + 34.846) - (31.454 + 0.432 + 40.804)
=40.121

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.132 + 50.584 + 35.458) - (44.166 + 0.427 + 28.614)
=22.967

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Valneva SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-96.599/527.532
=-18.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE EBIT Related Terms

Valneva SE EBIT Historical Data

* Premium members only.

The historical data trend for Valneva SE's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE EBIT Chart

Valneva SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.02 -125.76 -75.30 12.50 -72.22

Valneva SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.78 -6.20 -37.80 -26.44 -26.16

WBO:VLA vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Valneva SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valneva SE EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Valneva SE's EV-to-EBIT falls into.


WBO:VLA
56GF Score
Valneva SE WBO:VLA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valneva SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-96.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-96.6 Mil mean?
Valneva SE (WBO:VLA) has a EBIT of €-96.6 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Valneva SE.
Is Valneva SE's EBIT too high?
Valneva SE's current EBIT is €-96.6 Mil. Overall, Valneva SE has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's EBIT compare to VRTX and REGN?
Valneva SE's EBIT of €-96.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Valneva SE. Valneva SE's current EBIT is €-96.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (WBO:VLA) is currently considered Fairly Valued. The stock's GF Value™ is €2.46, compared to a current price of €2.23 — trading 9.4% below its estimated fair value. The current EBIT is €-96.6 Mil. Valneva SE's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Valneva SE (WBO:VLA), the current EBIT is €-96.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (WBO:VLA) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of €2.23 is trading 9.4% below its estimated GF Value™ of €2.46. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for WBO:VLA:

  • EBIT: €-96.6 Mil
  • GF Value™: €2.46 vs. price of €2.23 (9.4% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the WBO:VLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
56GF Score

Get the complete analysis for WBO:VLA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.23
Price
€2.46
GF Value